SEC Form 4 · accession 0000904454-17-000133
Paratek Pharmaceuticals, Inc. · PRTK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Bigham
Officer — Chairman and CEO · Director
Period of report
Feb 6, 2017
Accepted (ET)
Feb 8, 2017 · 6:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178711
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 6, 2017 | S | 30 | $15.20 | D | 99,970 | D | |
| Common StockF1 | Feb 6, 2017 | S | 1,082 | $15.15 | D | 98,888 | D | |
| Common StockF1 | Feb 6, 2017 | S | 2,104 | $15.10 | D | 96,784 | D | |
| Common StockF1 | Feb 6, 2017 | S | 32 | $15.075 | D | 96,752 | D | |
| Common StockF1 | Feb 6, 2017 | S | 1,752 | $15.05 | D | 95,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to Rule 10b5-1 trading plan.